Market Research Reports, Inc. has announced the addition of “Global Collaborative R&D Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015” research report to their website http://www.MarketResearchReports.com

Lewes, DE -- (SBWire) -- 08/18/2015 --The Global Collaborative R&D Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015 report provides comprehensive understanding and unprecedented access to the collaborative R&D partnering deals and agreements entered into by the worlds leading healthcare companies.

Description
The Global Collaborative R&D Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015 report provides comprehensive understanding and unprecedented access to the collaborative R&D deals and agreements entered into by the worlds leading life science companies.

The report provides a detailed understand and analysis of how and why companies enter collaborative R&D deals.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual collaborative R&D contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of collaborative R&D dealmaking and business activities.

The initial chapters of this report provide an orientation of collaborative R&D dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in collaborative R&D as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of collaborative R&D deals. The chapter includes numerous case studies to enable understanding of both pure collaborative R&D deals and multicomponent deals where collaborative R&D forms a part.

Chapter 4 provides a review of the leading collaborative R&D deals since 2010. Deals are listed by headline value, signed by bigpharma, most active bigpharma, signed by bigbiotech, most active bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive review of collaborative R&D financials for deals announced since 2010, including headline value, upfront, milestone payments and royalty rates by stage of development, providing both benchmark data and access to individual deal financials.

Chapters 6 and 7 provide a comprehensive listing of the top 50 bigpharma and bigbiotech companies with a brief summary followed by a comprehensive listing of collaborative R&D deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 8 provides a comprehensive and detailed review of collaborative R&D deals signed and announced since 2010 where a contract document is available. The chapter is organized by company A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report also includes numerous table and figures that illustrate the trends and activities in collaborative R&D dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about collaborative R&D as an opportunity to participate in the commercialization of either candidate compounds in development or products already on the market.

In addition, a comprehensive appendix is provided organized by collaborative R&D company A-Z , stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about collaborative R&D partnering in the research, development and commercialization of technologies and products.

Report scope
Global Collaborative R&D Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015 is intended to provide the reader with an in-depth understanding of the collaborative R&D trends and structure of deals entered into by leading life science companies worldwide.

Global Collaborative R&D Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015 includes:

- Trends in collaborative R&D dealmaking in the biopharma industry since 2010
- Analysis of collaborative R&D deal structure
- Case studies of real-life collaborative R&D deals
- Comprehensive listing of collaborative R&D deals since 2010
- Access to collaborative R&D contract documents
- Key financial benchmarks for headline, upfront, milestone and royalty rates
- The leading collaborative R&D deals by value since 2010
- Most active collaborative R&D dealmakers since 2010
- The leading collaborative R&D partnering resources

In Global Collaborative R&D Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015 available deals and contracts are listed by:

- Company A-Z
- Headline value
- Therapeutic area
- Technology type

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

The Global Collaborative R&D Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015 report provides comprehensive access to available contract documents for licensing deals. Analyzing actual contract agreements allows assessment of the following:

- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How do milestone align with clinical stage development phases?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Collaborative R&D Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015 provides the reader with the following key benefits:

- In-depth understanding of collaborative R&D deal trends since 2010
- Analysis of the structure of collaborative R&D agreements with numerous real life case studies
- Comprehensive listing of all collaborative R&D deals since 2010, together with deal terms, value and press release
- Comprehensive access to actual collaborative R&D contracts entered into by the world's life science companies
- Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
- Insight into the terms included in a collaborative R&D agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Spanning over 669 pages "Global Collaborative R&D Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015" report covers Executive Summary, Introduction, Trends in collaborative R&D dealmaking, Overview of collaborative R&D deal structure, Leading collaborative R&D deals, Collaborative R&D deal term benchmarks, Big pharma collaborative R&D deals, Big biotech collaborative R&D deals, Collaborative R&D contract directory 2009-2015, Appendix.

For further information on this report, please visit-
http://www.marketresearchreports.com/current-partnering/global-collaborative-rd-terms-agreements-pharma-biotech-diagnostics-2010-2015

Related Reports:

1st- Global Pharma and Biotech M&A Trends 2010-2015 - visit at:
http://www.marketresearchreports.com/current-partnering/global-pharma-and-biotech-ma-trends-2010-2015

2nd- Global Diagnostics Partnering 2010-2015: Deal trends, players, financials and forecasts - visit at:
http://www.marketresearchreports.com/current-partnering/global-diagnostics-partnering-2010-2015-deal-trends-players-financials-and

3rd- Global Molecular Diagnostics 2010-2015: Deal trends, players, financials and forecasts - visit at:
http://www.marketresearchreports.com/current-partnering/global-molecular-diagnostics-2010-2015-deal-trends-players-financials-and

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter